Contact Person
    Nicole Mastrell

    Event Manager & PA to CEO
    Phone: (M) +45 6141 8634

    NDA HTA Seminar – The future of Health Technology Assessment in Europe

    On the 24th October NDA Group invites you and your colleagues in the market access department/HEOR to a complimentary seminar on the future of HTA.

    The market access environment is getting increasingly challenging. The ability to develop plans and strategies for access, for today as well as tomorrow, is critical to bring new medicines to patients.

    With 17 years as Executive Director for NICE, Carole Longson has unparalleled experience in understanding how HTA bodies work and collaborate in the EU. In June 2018 she joined NDA as a HTA Advisor.

    This seminar will discuss the past, present and future of HTA and market access. On stage Carole is joined by an esteemed panel comprising Dr Steffen Thirstrup, former Division Head at the Danish Medicines Agency and CHMP member, Dr Fredrik Andersson, Senior Director Global HEOR Ferring and Mark Aagren, Senior Director Market Access and Public Affairs ALK.

    Date: 24 October 2018
    Time: 8:30 – 12:00
    Venue: Medicon Valley Alliance, Arne Jacobsens Alle 15 , 2300 Ørestad City, Copenhagen, Denmark, Ground floor




    Registration & light breakfast


    Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd

    Session 1 – Challenges on development programs for new drugs
    Professor Steffen Thirstrup, Director, NDA Regulatory Advisory Board (previous Danish Medicines Agency / EMA)

    • Clinical trial guidelines and how to deliver patient centric critical data for regulatory and HTA bodies. Implications and mitigations.

    Session 2 – HTA alignment in Europe – what does the future of HTA have in store?
    Professor Carole Longson, Life Science Policy, Research and Market Access, NDA Advisory Services Ltd (previous executive Director NICE UK)

    Conversation leaders at stage:
    Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd
    Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd
    Dr Fredrik Andersson, Senior Dir Global HEOR Ferring
    Mark Aagren, Senior Director Market Access and Public Affairs ALK

    • EU clinical effectiveness review (Parliaments proposal), where is it going? Will EU get a ‘super-HTA body’ in the future?

    • EUnetHTA and EMA, directions and implications for future collaborations

    • NICE after Brexit?


    End of meeting – conclusions and take-home messages
    Claes Buxfeldt, HTA Director, NDA Advisory Services Ltd

    12:00 – 1400

    Ask the Experts
    Book a 20 min slot for a chat directly with our Experts by contacting

    About NDA Group
    NDA Group is a world leading drug development consultancy. Over the past five years NDA has supported over 40% of the new medicinal products approved in Europe.


    Steffen Thirstrup
    Director, NDA Regulatory Advisory Board
    NDA Advisory Services Ltd

    Carole Longson
    Life Science Policy, Research and Market Access
    NDA Advisory Services Ltd

     Claes Buxfeldt
    HTA Director
    NDA Advisory Services Ltd

    Organized by:

    In collaboration with: